Skip to content

Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd:YAG laser for the treatment of melasma in Asians: a randomized, split-face study

Combined isobutylamido thiazolyl resorcinol and low fluence Q-switched Nd:YAG laser for the treatment of melasma in Asians: a randomized, split-face study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200410010
Enrollment
Unknown
Registered
2020-04-10
Start date
2019-10-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of melasma. melasma laser hyperpigmentation

Interventions

One side of the face was randomized to apply 0.15% ITR containing product for 12 weeks. The Low fluence QS laser was performed every 1 week for 5 sessions. ,Cream base was used for placebo. The other
Active Comparator Drug,Placebo Comparator Drug
ITR and low&#45
fluence QS Nd:YAG,Placebo and low&#45
fluence QS Nd:YAG

Sponsors

Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Lead Sponsor
Division of Dermatology&#44
Collaborator
Department of medicine&#44
Collaborator
Faculty of Medicine&#44
Collaborator
Ramathibodi hospital
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 0 Years

Inclusion criteria

Inclusion criteria: Symmetrical mixed type melasma on both malar areas

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Having a dermatological condition on the treating area History of topical or systemic therapy for melasma within 1 mont History of laser therapy within 6 months

Design outcomes

Primary

MeasureTime frame
mean relative lightness index evaluate at every visit colorimeter (DSM II ColorMeter®),Clinical changes evaluate at every visit Melasma Area and Severity Index on the malar area (MASIm),patient satisfaction scores evaluate at every visit visual analogue scale on improvement of melasma

Secondary

MeasureTime frame
Adverse events evaluate at every visit Dermatologist evaluation and patients' feedback

Countries

Thailand

Contacts

Public ContactVasanop Vachiramon

Faculty of Medicine, Ramathibodi hospital

vasanop@gmail.com022011211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026